/
Other
Growth
67
Pipeline Programs↗
34
Active Trials↗
49
Companies Involved↗
Growth is a moderately active landscape with 67 programs across 49 companies. The most active players are Novo Nordisk, Sanofi, Shaanxi Micot Pharmaceutical Technology Co., Ltd.. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical52
Phase 16
Phase 24
Phase 35
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
56 of 63 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 63 classified programs, each share of the total. Modality classified for 99% of 67 pipeline programs.
Analysis
Trial Status
400
clinical trials
Completed249 · 62%
Unknown status58 · 14%
Terminated45 · 11%
Recruiting18 · 5%
Withdrawn10 · 3%
Active, not recruiting9 · 2%
Other11 · 3%
Clinical Trials
Trial Activity
400 trials
The MOM-CARE Trial : Evaluating Antenatal and Postnatal MMSPlus for Improved Infant Birth and Growth Outcomes
Recruiting·—·Phase 3·NCT07029282·3,000 enrolled
Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.
Recruiting·—·N/A·NCT06772064·115 enrolled
Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
Recruiting·—·Phase 2·NCT05355272·20 enrolled
Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS)
Recruiting·—·N/A·NCT06110910·10,000 enrolled
Page 1 of 27
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)